High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
The Big Market Report Take
This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments.
Not financial advice. The Big Market Report aggregates news for informational purposes only. Nothing on this site constitutes investment advice. Equities and other securities are subject to market risk. Always do your own research and consult a qualified financial advisor before making any investment decisions. Full disclaimer →
Never miss a story
More from this section
What Happens to Your Investments If the Stock Market Crashes?The Motley Fool1h ago